LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Stoelzle – 15th May 2025

FDA committee backs GSK’s multiple myeloma drug

GlaxoSmithKline’s belantamab mafodotin has been backed for approval to treat relapsed/refractory multiple myeloma by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC).

The Committee voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.

The decision was based on data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme, including the pivotal DREAMM-2 study, in which the drug demonstrated a 31% overall response rate (ORR) in heavily pre-treated patients who had actively progressing multiple myeloma that had worsened despite current standard of care.

“We are pleased the committee recognised the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options,” said Dr Axel Hoos, senior vice president and head of Oncology R&D, GSK. “We look forward to working with the FDA as they complete their review of our Biologics License Application.”

The drug is also currently under review in Europe.

Scott Pharma – 25.03.2025
Bespak – 21.05.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025
Drug Discovery 2025, ELRIG – 04.07.2025